Market Watch for Intellipharmaceutics International Inc. Issued by Beacon Equity

DALLAS, March 16, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Intellipharmaceutics International Inc. IPCI. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/IPCI

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Intellipharmaceutics International Inc. (IPCI) engages in the research, development and commercialization of controlled-release drug technologies. The Company has 15 drug programs in development that address various therapeutic areas, including neurology, cardiovascular, Gastro-Intestinal Tract (GIT), pain and infection. Partnered with Par Pharmaceutical Companies Inc., the Company's lead drug product, a generic form of Focalin XR, is under review by the Food and Drug Administration for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Another one of the Company's leading drug candidate is Rexista, a competing drug to Oxycodone, developed to alleviate pain.

In the report, the analyst notes:

"With the development of its four leading drug products, including Generic Focalin XR, Generic Effexor XR, Rexista (Oxycodone) and Generic Coreg CR, the Company attempts to capture a portion of a combined market of more than $6.0 billion in annual revenue.   Presently, revenue derived from its competitors' proprietary drugs Focalin XR, Effexor XR, Coreg CR and Oxycodone RX total $350 million, $3.9 billion, $300 million and $2.0 billion, respectively.

"The novel approach of manipulating the delivery of the above-named drug therapies via the Company's novel Hypermatrix(TM) concept allows the Company a margin of competitive advantage within the pharmaceutical space.   Its Hypermatrix delivery system concept is designed to optimize Nature's hyper-dimensionality as it relates to drug therapies."

To read the entire report visit: http://www.beaconequity.com/i/IPCI

See what investors are saying about these stocks at penny stock forum.

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.